Drug Profile
Research programme: targeted EZH2 inhibitors - Epizyme/Eisai
Alternative Names: EPZ 5687; EPZ005687; EZH2 inhibitors - Epizyme/EisaiLatest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Epizyme
- Developer Eisai Co Ltd; Epizyme
- Class Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Lymphoma; Solid tumours